Search the Newsreel

Oric Pharmaceuticals Inc (ORIC) Balance Sheet

This article provides a detailed balance sheet for Oric Pharmaceuticals Inc (ORIC), presenting quarterly and annual financial data spanning several years. It includes key financial metrics such as cash and short-term investments, total assets, liabilities, and shareholders' equity, along with year-over-year percentage changes. The …

Does ORIC (ORIC) Retaining Rinzimetostat Rights Hint At A High-Conviction, High-Risk Development Strategy?

Oric Pharmaceuticals (ORIC) has initiated a global Phase 3 trial for rinzimetostat in metastatic castration-resistant prostate cancer, retaining full development and commercial rights while Bayer supplies a key drug at no cost. This strategy positions ORIC as a high-risk, pre-revenue biotech with significant clinical …

Oric Pharmaceuticals Inc (ORIC) Cash Flow

This article provides a detailed cash flow statement for Oric Pharmaceuticals Inc (ORIC), including operating, investing, and financing cash flows presented quarterly and annually. It highlights key financial figures such as net income from continuing operations, capital expenditures, and free cash flow over several …

Oric Pharmaceuticals Inc (ORIC) Institutional Confidence

The article provides an overview of Oric Pharmaceuticals Inc. (ORIC) with a focus on its institutional confidence, highlighting major institutional shareholders and their recent activity. Key investors like Nextech Invest, EcoR1 Capital, and Viking Global Investors are listed with their shareholdings, alongside the company's …

Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded at Wall Street Zen

Wall Street Zen upgraded Oric Pharmaceuticals (NASDAQ:ORIC) from a "strong sell" to a "sell" rating. Despite this, the stock holds a "Moderate Buy" consensus from other analysts with an average target price of $19.27. Oric Pharmaceuticals saw an 11.1% gain in Friday trading but …

Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 5.4% - Time to Buy?

Oric Pharmaceuticals (NASDAQ:ORIC) saw its stock price rise 5.4% on Friday, trading at $11.4820 with lower-than-average volume. Despite an average "Moderate Buy" rating and a $19.27 consensus price target from analysts, the clinical-stage biopharmaceutical firm recently reported a quarterly EPS loss of $0.34, missing …

Siren L.L.C. Has $37.99 Million Holdings in Oric Pharmaceuticals, Inc. $ORIC

Siren L.L.C. significantly increased its stake in Oric Pharmaceuticals (NASDAQ:ORIC) by 197.6% in the first quarter, now holding 2.99 million shares valued at approximately $37.99 million. Other institutional investors also adjusted their positions, with overall institutional ownership reaching 95.05%. Analysts have a "Moderate Buy" …

Discipline and Rules-Based Execution in ORIC Response

Oric Pharmaceuticals Inc. (NASDAQ: ORIC) is exhibiting mixed sentiment across time horizons, indicating potential choppiness. AI models have generated three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop levels, targeting an exceptional 81.7:1 risk-reward setup. Investors are advised …

ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

ORIC Pharmaceuticals announced three poster presentations for the European Society for Medical Oncology (ESMO) Congress 2026. The presentations will highlight data on enozertinib for EGFR atypical NSCLC and rinzimetostat for mCRPC, including details on the ongoing Himalayas-1 Phase 3 study and its potential to …

Orica (ASX:ORI) Shares Close Lower While Outperforms the Mining Sector

How ORIC’s Global Phase 3 Rinzimetostat Trial with Bayer’s NUBEQA Has Changed Its Investment Story (ORIC)

Oric Pharmaceuticals has initiated the Himalayas-1 global Phase 3 trial for rinzimetostat with Bayer’s NUBEQA for metastatic castration-resistant prostate cancer, enrolling about 600 patients. Bayer supplies darolutamide at no cost, and ORIC retains full global rights to rinzimetostat. This trial solidifies rinzimetostat as a …

Meteoric Resources (ASX:MEI) Gains as Rare Earths Interest Remains Hot

ORIC Forecast — Price Target — Prediction for 2027

Meteoric Resources NL (MEI) Receives a Buy from Macquarie

Meteoric Resources NL's (ASX:MEI) Path To Profitability

We Think You Should Be Aware Of Some Concerning Factors In Oricon Enterprises' (NSE:ORICONENT) Earnings

Oricon Enterprises Schedules Board Meeting on May 29, 2026 to Approve Q4FY26 Financial Results and Dividend

ORIC Q1 2026 Earnings: Narrower-Than-Expected Loss, Pipeline Progress Keeps Focus on Key Milestones - Post-Earnings Reaction

Four Days Left Until Orica Limited (ASX:ORI) Trades Ex-Dividend

Meteoric Resources (ASX:MEI) Gains Momentum on Funding Boost — Here’s What Matters

Stocks With Rising Relative Strength: Oric Pharmaceuticals

Oricon Enterprises Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Oricon Enterprises Submits SEBI Compliance Certificate for Q4 FY26

Meteoric Resources (ASX:MEI) Stock Draws Broker Attention Amid Recent Share Performance Moves

Why ASX, CSL, GQG, and Meteoric Resources shares are sinking today

Is Orica Limited's (ASX:ORI) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Oricon Enterprises Announces Major Board Restructuring with Three New Director Appointments

Why We're Not Concerned About Orica Limited's (ASX:ORI) Share Price

Oric Pharmaceuticals Stock Sees Healthy RS Rating Jump To 80

Oricon Enterprises Completes Sale of Thane Manufacturing Unit for ₹2.38 Crores

Oricon Enterprises Ltd. Share Price Today - Oricon Enterprises Ltd. Stock Price Live NSE/BSE

Orica Limited (OTC: OCLDF) Stock Price, News & Analysis

Oricon Enterprises Divests Metal Crown Seals and Roll-On Pilfer-Proof Closures Business to Guala Closures India

ORIC Pharmaceuticals Issues 292.5K Stock Options, 79K RSUs to New Employee

Adarsh Somani and Associates to Acquire 10.31% Stake in Oricon Enterprises

Meteoric Resources NL's (ASX:MEI) Shift From Loss To Profit